+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations

Histological response of peritoneal carcinomatosis after hyperthermic intraperitoneal chemoperfusion (HIPEC) in experimental investigations

Bmc Cancer 6: 162

In selected patients with peritoneal carcinomatosis from colorectal cancer prognosis can be improved by hyperthermic intraperitoneal chemotherapy (HIPEC) after cytoreductive surgery. The aim of this study was to evaluate the tumor response of peritoneal carcinomatosis in tumor-bearing rats treated with HIPEC. CC531 colon carcinoma (2,5 x 106 cells), implanted intraperitoneally in Wag/Rija rats, was treated by hyperthermic intraperitoneal chemotherapy. After 10 days of tumor growth the animals were randomized into five groups of six animals each: group I: control (n = 6), group II: sham operated animals (n = 6), group III: hyperthermic intraperitoneal perfusion (HIP) without cytostatic drugs, group IV: HIPEC with mitomycin C in a concentration of 15 mg/m2 (n = 6), group V: mitomycin C i.p. alone in a concentration of 10 mg/m2 (n = 6). After 10 days the extent of tumor spread and histological outcome were analysed by autopsy. All control animals developed extensive intraperitoneal tumor growth. Histological tumor load was significantly reduced in group III and group V and was lowest in group IV. In group II tumor load was significantly higher than in group I. Implanted metastases were significantly decreased in group IV compared with group I and group II. These findings indicate that HIPEC is an effective treatment for peritoneal carcinomatosis in this animal model. HIPEC reduced macroscopic and microscopic intraperitoneal tumor spread.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 049229919

Download citation: RISBibTeXText

PMID: 16792796

DOI: 10.1186/1471-2407-6-162

Related references

Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis. Annals of Surgical Oncology 21(9): 3023-3028, 2015

Hyperthermic intraperitoneal chemotherapy (HIPEC). Mechanisms of action and the role of HIPEC in the treatment of peritoneal carcinomatosis. Annali Italiani di Chirurgia 89: 513-527, 2019

Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children. Journal of Pediatric Surgery 42(9): E17-E21, 2007

Diffuse and gross peritoneal carcinomatosis treated by intraperitoneal hyperthermic chemoperfusion. Cancer Treatment and Research 82: 211-219, 1996

Phase II Trial of Laparoscopic Hyperthermic Intraperitoneal Chemoperfusion for Peritoneal Carcinomatosis or Positive Peritoneal Cytology in Patients with Gastric Adenocarcinoma. Annals of Surgical Oncology 24(11): 3338-3344, 2017

Experimental study of antitumour activity and effects on leukocyte count of intraperitoneal administration and hyperthermic intraperitoneal chemoperfusion (HIPEC) with dioxadet in a rat model of ovarian cancer. Journal of ChemoTherapy 28(3): 203-209, 2017

Safety and efficacy of hyperthermic intraperitoneal chemoperfusion with high-dose oxaliplatin in patients with peritoneal carcinomatosis. Annals of Surgical Oncology 15(2): 535-541, 2007

Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 116(16): 3756-3762, 2010

Is there a role for intraperitoneal administration of heparin in hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal carcinomatosis of colorectal cancer origin? Current data and future orientations. Medical Hypotheses 81(2): 240-242, 2014

Use of hyperthermic intraperitoneal chemotherapy (HIPEC) in management of peritoneal carcinomatosis from colorectal origin. Surgical Technology International 14: 125-130, 2006

Rationale for hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment or prevention of peritoneal carcinomatosis. Acta Chirurgica Belgica 104(4): 377-383, 2004

Significance of diaphragmatic resections and thoracic chemoperfusion on outcomes of peritoneal surface disease treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Annals of Surgical Oncology 21(13): 4226-4231, 2015

Peritonectomy and hyperthermic intraperitoneal chemotherapy (HIPEC) for ovarian peritoneal carcinomatosis: an argued role. Gynecologic Oncology 117(1): 146-147, 2010

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis HIPEC the Danish experience. 2013

Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). Minerva Chirurgica 69(1): 27-35, 2014